Vigmed granted a first patent for a needlesafe lancet.
The Swedish Patent and Registration Office (PRV) has announced that it intends to grant Vigmed a Swedish patent for a needlesafe product within the area of blood collection.
The market for blood collection products (lancets) is a high volume segment. Vigmed has developed a new type of safety technology in this field. This safety technology enables very cost-effective manufacturing, compared to the safety lancets available on the market today. The safety construction is also adapted to other needle products with short lengths, for example insulin needles etc.
"This segment is very interesting for Vigmed’s product portfolio and future business development, and we have already developed functional prototypes of this new product category. We possess today a very solid and exciting innovation portfolio, however Vigmed is currently focusing on commercializing the products already launched and available today. We will therefore evaluate other business opportunities for this product segment”, says Vigmed CEO Finn Ketler.
Vigmed has so far, nationally and internationally, filed more than 75 patents and patent applications based on 15 patent families and within three innovation platforms. The Company owns all of its patents and patent applications without restrictions.
Vigmed’s strategy is to protect the company's technology and products in all geographically important markets. Vigmed intends to expand its patent portfolio continuously with both offensive and defensive patents and utility model rights, based on a number of new innovation platforms.
For further information contact:
Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Finn Ketler +46 42 600 5311
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has 20 employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor.
Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor